What is a Center for Genomic Epidemiology?

A center for genomic epidemiology is a research hub that uses DNA sequencing to track how infectious diseases spread, evolve, and resist treatment. The best-known example is the Center for Genomic Epidemiology (CGE) based at the Technical University of Denmark, which develops freely available online tools that let microbiologists around the world analyze pathogen genomes without needing advanced bioinformatics training.¹ But the concept extends well beyond a single institution. Genomic epidemiology programs now operate inside hospitals, public health agencies, and university research networks worldwide, all sharing a common mission: reading the genetic code of pathogens to answer questions that older laboratory methods could not.

Why Sequencing Replaced the Old Gold Standard

For roughly two decades, public health labs relied on a technique called pulsed-field gel electrophoresis (PFGE) to fingerprint bacteria during outbreak investigations. PFGE works by cutting a pathogen’s DNA into fragments and sorting them by size, producing a banding pattern that looks a bit like a barcode. If two isolates from different patients showed the same barcode, they were assumed to be closely related. The problem is that PFGE is blunt. A direct comparison of PFGE and whole-genome sequencing (WGS) across hospital-associated pathogens found that about 29% of isolates that looked identical by PFGE were actually unrelated when examined at single-nucleotide resolution. And in the other direction, some truly related isolates appeared different by PFGE, particularly in species prone to rapid gene swapping.²

A large-scale French study of Listeria monocytogenes confirmed this at national level. When researchers ran over 2,700 isolates through both PFGE and a WGS-based typing method side by side, the sequencing approach was significantly better at separating unrelated strains and grouping truly related ones. It identified outbreaks earlier and improved the ability to trace contamination back to a source.³ These findings are the reason centers for genomic epidemiology exist: sequencing the full genome of a pathogen gives you a far sharper picture of who infected whom, and when, than any older fingerprinting method could.

What These Centers Actually Provide

A center for genomic epidemiology is not just a sequencing lab. Its real contribution is the bioinformatics layer on top of the raw sequence data. Sequencing a bacterial genome produces millions of short DNA reads. Turning those reads into useful epidemiological information requires specialized software pipelines that assemble the reads, compare them against reference genomes, and identify the tiny genetic differences that distinguish one strain from another.

The DTU-based CGE suite, for instance, includes tools like ResFinder for detecting antimicrobial resistance genes, and its platform was specifically designed so that researchers without computational expertise could upload their sequence data and get interpretable results.¹ Other pipelines serve different purposes. SNVPhyl, for example, identifies single-nucleotide variants across a group of isolates and builds a family tree showing how they are related, all within a user-friendly framework that makes analyses reproducible.⁴ Gen2Epi takes a different approach, automating the process from raw sequencing reads all the way to assembled genomes annotated with resistance and epidemiological data for gonorrhea surveillance.⁵

The common thread is accessibility. Genomic epidemiology generates enormous amounts of data, and the software that interprets it is what makes the whole enterprise useful to the frontline microbiologist or the hospital infection control team who do not have a background in computational biology.

Tracking Foodborne Outbreaks

One of the highest-profile applications of genomic epidemiology is in food safety. When people in different parts of a country get sick from the same contaminated product, genomic sequencing can link their isolates even when traditional methods would not have flagged a connection. The European Union recognized this advantage by adopting a regulation requiring member states to perform WGS on isolates of five key foodborne pathogens, including Salmonella, Listeria, and pathogenic E. coli, during outbreak investigations, and to share that data across borders.⁶

In the United States, the GenomeTrakr network has been performing WGS-based surveillance of foodborne pathogens for years. A 2015 proficiency test distributed identical isolates to 21 participating labs and found that sequencing results were highly reproducible: the same strain cultured and sequenced in different cities could be reliably identified as coming from the same source.⁷ This kind of network-wide consistency is what makes it possible to link a cluster of illnesses in one state to a contaminated food product identified in another.

Inside the Hospital

Genomic epidemiology is not limited to national surveillance networks. Some of its most immediate practical impact happens within individual hospitals. Healthcare-associated infections, such as MRSA and drug-resistant enterococci, spread through patient contact, contaminated surfaces, and the hands of healthcare workers. When two patients on the same ward test positive for the same species, infection control teams need to know whether the cases are linked or coincidental. Sequencing answers that question with a level of certainty that older methods cannot match.

A seven-year genomic epidemiology program at an academic medical center found that embedding sequencing directly within the hospital’s infection control team enabled rapid outbreak investigations and timely implementation of prevention measures. The program also demonstrated that metagenomic sequencing, which does not require growing the pathogen in culture first, could assess a broad range of viral, bacterial, and fungal threats including emerging microbes.⁸

A study focused specifically on MRSA at another hospital illustrated both sides of the coin. Genomic data identified 17 clusters consistent with hospital transmission and prompted additional infection control actions in most of them. But it also identified 38 instances where patients on the same ward carried unrelated MRSA isolates that would have looked like an outbreak by conventional methods. In six of those false alarms, the genomic evidence led teams to de-escalate their investigation and redirect resources elsewhere.⁹ That ability to rule out a connection is just as valuable as confirming one, because outbreak responses are expensive and disruptive.

Mapping Antimicrobial Resistance

Antibiotic resistance is one of the most urgent public health threats worldwide, and genomic epidemiology has become a central tool for understanding how resistance genes move across bacterial populations. Resistance does not always evolve locally. Genes conferring resistance to drugs can hitch a ride on mobile genetic elements like plasmids and jump between species, sometimes spreading globally before anyone notices.

A recent study illustrating this screened over 700,000 bacterial genomes and identified nearly 6,000 isolates carrying variants of the cfr family of resistance genes, which confer resistance to multiple antibiotic classes. The analysis resolved these into 11 distinct variant clusters, including two newly identified types, and showed that some variants were carried mainly on chromosomes while others traveled primarily on plasmids, a distinction that matters because plasmid-borne genes spread far more easily between bacterial species.¹⁰ This kind of global-scale resistance mapping is only possible because genomic epidemiology centers have built the databases and workflows that allow researchers to compare isolates across continents.

Viral Surveillance and the COVID-19 Watershed

The COVID-19 pandemic dramatically accelerated the adoption of genomic epidemiology for viral diseases. Before the pandemic, sequencing viruses for surveillance was relatively niche. By 2021, countries were racing to sequence as many SARS-CoV-2 samples as possible to track the emergence and spread of new variants. Researchers used phylodynamic modeling, essentially building evolutionary family trees of the virus, to estimate how transmissible different variants were and how quickly they spread through populations.¹¹ Genomic surveillance proved critical for the early detection of emerging variants, supporting proactive rather than reactive public health responses.¹²

One unexpected benefit of the pandemic was the expansion of wastewater surveillance. Because infected individuals shed viral RNA in their feces, sampling sewage can provide an unbiased snapshot of which variants are circulating in a community, independent of clinical testing rates. A Utah study demonstrated that wastewater genomic surveillance detected the Omicron variant before clinical surveillance flagged it, providing an early warning that gave public health officials more lead time.¹³ This approach is particularly valuable in settings where clinical testing is limited. A study in Morocco showed that estimating SARS-CoV-2 levels from wastewater correlated positively with reported case numbers, demonstrating feasibility in a resource-constrained environment.¹⁴ Wastewater-based genomic surveillance has now been widely recognized as an effective complement to traditional clinical surveillance for monitoring known and emerging mutations.¹⁵

The One Health Connection

Infectious diseases do not respect the boundary between humans and animals. Roughly 60% of known infectious diseases in humans are zoonotic, meaning they originate in animals. The One Health framework, which treats human, animal, and environmental health as interconnected, maps naturally onto what genomic epidemiology does well: comparing pathogen genomes across species and settings to find transmission links.

A scoping review identified 114 studies published between 2005 and 2022 that applied genomic epidemiology to zoonotic disease transmission across human, animal, and environmental domains.¹⁶ In practice, this means sequencing E. coli or Salmonella from a sick patient, from a farm animal, from a food product, and from a river, and seeing whether the genomes match. An Australian study did exactly this with over 5,400 E. coli genomes spanning humans, companion animals, livestock, wildlife, food, and the environment over 36 years. The researchers found clusters that spanned every source they analyzed, identifying specific bacterial lineages that repeatedly crossed between animals, people, and the environment.¹⁷ Without genomics, connections like these would remain invisible.

Ensuring Data Quality Across Borders

Genomic epidemiology depends on consistent data. If two labs sequence the same isolate and get meaningfully different results, cross-border comparisons fall apart. This is why proficiency testing programs exist. The Global Microbial Identifier initiative has been working to establish inter-laboratory sequencing proficiency tests that verify whether participating labs can produce reliable data.¹⁸

A 2020 genomic proficiency test organized by the Technical University of Denmark sent identical Salmonella, E. coli, and Campylobacter samples to 21 laboratories across 21 European countries. Most labs delivered high-quality data, with only two identified as overall underperforming.¹⁹ These exercises build confidence that when a French lab and a German lab compare genomic data, they are speaking the same language. The vision is a globally connected system of pathogen genome databases that enables faster detection and response to outbreaks wherever they start.²⁰

The Economic Case

Genomic surveillance is not cheap. Sequencers, reagents, trained staff, and data storage all cost money, and for countries deciding whether to invest, the question of return on investment matters. A systematic review of economic evaluations found that all studies examined supported the use of WGS as a surveillance tool on economic grounds.²¹ The logic is straightforward: catching an outbreak earlier means fewer infections, fewer hospitalizations, and fewer recalls, all of which are expensive.

That said, there is no standardized way to calculate the return for a multi-pathogen surveillance system. Local disease burdens, health infrastructure, and the broader societal benefits are all context-dependent and difficult to quantify.²² A cost comparison between continuous surveillance and outbreak-triggered sequencing suggests that although comprehensive surveillance requires higher upfront and steady investment, it could yield substantial long-term savings by averting large-scale outbreaks.²³ For many countries, the argument boils down to “invest now, save later,” but the difficulty lies in proving the counterfactual: how do you measure the cost of an outbreak that did not happen?

Building Capacity Where It Is Needed Most

Genomic epidemiology’s benefits are unevenly distributed. High-income countries have invested heavily in sequencing infrastructure, while many low- and middle-income countries lack the equipment, training, and connectivity to participate fully. This gap matters because pathogens do not respect national borders, and surveillance is only as strong as its weakest link.

Efforts to build capacity in the African Great Lakes region, for example, have highlighted that while collaborative initiatives exist, they tend to be ad-hoc responses to emergencies rather than sustainable long-term programs. Building and strengthening local genomic surveillance in resource-limited settings requires longer collaborations that support readiness even when funding dries up.²⁴ Portable sequencing technologies and cloud-based analysis platforms are part of the solution, as they shift the work from centralized labs to field-based settings closer to where outbreaks actually start.²⁵

The ethical dimensions are real, too. Large-scale genomic data collection in developing countries raises questions about research ownership, intellectual property, informed consent, and the privacy of participants, particularly when the research is far upstream from any therapeutic benefit.²⁶ International collaborations also raise governance issues about sample export, the use of archived specimens, and ensuring that scientists in low-income countries are genuine partners rather than sample providers. Sustainable, mutually beneficial partnerships depend on addressing data sharing and capacity building upfront.²⁷

Metagenomics and What Comes Next

Traditional genomic epidemiology requires you to know roughly what you are looking for. You grow a bacterial colony, extract its DNA, and sequence it. Metagenomics skips the culturing step entirely, sequencing all the genetic material in a sample at once, whether that sample is a patient’s blood, a sewage grab, or a swab from a hospital ventilator. Because the approach is pathogen-agnostic, it can detect unknown and novel infections, investigate outbreaks with no obvious cause, and monitor for emerging threats that nobody has thought to test for yet.²⁸

The trade-off is complexity. Metagenomic data sets are enormous and messy, containing genetic material from the patient, their normal microbial flora, and any pathogens present, all jumbled together. Parsing that data requires serious computational resources and carefully validated pipelines. But as sequencing costs continue to drop and bioinformatics tools mature, metagenomics is increasingly being folded into the toolkit of centers for genomic epidemiology. For hospitals, it offers the possibility of diagnosing infections that cultures miss. For public health, it represents the closest thing we have to an early warning system that does not require anyone to guess in advance which pathogen to look for.